<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01866423</url>
  </required_header>
  <id_info>
    <org_study_id>4P-13-1</org_study_id>
    <secondary_id>NCI-2013-01013</secondary_id>
    <secondary_id>IISR-2012-M000668</secondary_id>
    <secondary_id>P30CA014089</secondary_id>
    <nct_id>NCT01866423</nct_id>
  </id_info>
  <brief_title>Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer</brief_title>
  <official_title>Phase 2 Trial of TAK-700 (Also Known as Orteronel) Without Prednisone for Metastatic Castration-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well orteronel works in treating patients with metastatic&#xD;
      hormone-resistant prostate cancer. Orteronel may stop the growth of tumor cells by blocking&#xD;
      some of the enzymes needed for cell growth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the relationship between circulating tumor cell (CTC)-based androgen receptor&#xD;
      (AR) expression level and &gt;=-50% prostate-specific antigen (PSA) decline following 12 weeks&#xD;
      of therapy with TAK-700 (orteronel).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess changes in PSA and CTC levels and time to PSA progression (best response,&#xD;
      decline at 12 weeks as continuous variable, etc.) with or without prior docetaxel-based&#xD;
      treatment.&#xD;
&#xD;
      II. To assess measurable disease response and time to radiographic disease progression for&#xD;
      castration-resistant prostate cancer (CRPC) with or without prior docetaxel-based treatment.&#xD;
&#xD;
      III. To explore relationships between endocrine and clinical responses.&#xD;
&#xD;
      IV. To confirm the safety of TAK-700 administered without prednisone in patients with&#xD;
      metastatic CRPC.&#xD;
&#xD;
      OUTLINE: Patients receive orteronel orally (PO) twice daily (BID) on days 1-28. Courses&#xD;
      repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Not progressing toward scientific goals&#xD;
  </why_stopped>
  <start_date type="Actual">October 25, 2013</start_date>
  <completion_date type="Actual">July 26, 2016</completion_date>
  <primary_completion_date type="Actual">July 23, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Androgen Receptor (AR) Protein Expression Levels in CTCs</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>The two-sample t-test will be used. Once association between AR protein expression levels and response is established, graphical methods such as receiver-operator curves (ROC) or more quantitative methods such as the maximal chi-square method to determine whether there might be a cut-point with either great sensitivity or great specificity (or both) for identifying a cohort with either a high or low likelihood of prostate-specific antigen (PSA) response.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PSA Response, Defined as Occurrence of PSA Decline to Greater Than or Equal to 50% From Baseline</measure>
    <time_frame>At 12 weeks</time_frame>
    <description>Standard descriptive methods will be used to summarize PSA. Values will be tabulated as outlined in the Prostate Cancer Working Group 2 (PCWG2) criteria and presented as Kaplan-Meier survival curves, as appropriate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best PSA Response</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Values will be tabulated as outlined in the PCWG2 criteria and presented as Kaplan-Meier survival curves, as appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in PSA</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Values will be tabulated as outlined in the PCWG2 criteria and presented as Kaplan-Meier survival curves, as appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 and PCWG2 Criteria</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Response will be tabulated descriptively with 95% confidence intervals (CIs) and Kaplan-Meier survival curves, as appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response Using RECIST Version 1.1 and PCWG2 Criteria</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Response will be tabulated descriptively with 95% CIs and Kaplan-Meier survival curves, as appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Grade 3 or Higher Toxicity</measure>
    <time_frame>30 days</time_frame>
    <description>Summary of grade 3 (per Common Terminology Criteria for Adverse Events (CTCAE v4.0) or higher toxicities which generally is described as a severe reaction or symptom.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Adenocarcinoma of the Prostate</condition>
  <condition>Hormone-resistant Prostate Cancer</condition>
  <condition>Recurrent Prostate Cancer</condition>
  <condition>Stage IV Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (orteronel)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive orteronel 300 mg PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>orteronel</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (orteronel)</arm_group_label>
    <other_name>TAK-700</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (orteronel)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          -  Voluntary written informed consent before performance of any study-related procedure&#xD;
             not part of normal medical care, with the understanding that consent may be withdrawn&#xD;
             by the subject at any time without prejudice to future medical care&#xD;
&#xD;
          -  Patients, even if surgically sterilized (i.e., status post vasectomy), who agree to&#xD;
             practice effective barrier contraception during the entire study treatment period and&#xD;
             for 4 months after the last dose of study drug, or&#xD;
&#xD;
          -  Agree to completely abstain from intercourse&#xD;
&#xD;
          -  Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be =&lt;&#xD;
             2.5 x the upper limit of normal (ULN)&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x ULN&#xD;
&#xD;
          -  Estimated creatinine clearance using the Cockcroft-Gault formula must be &gt; 40&#xD;
             mL/minute&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1500 cells/microliter&#xD;
&#xD;
          -  Platelet count &gt;= 100,000 cells/microliter&#xD;
&#xD;
          -  Testosterone &lt; 50 ng/dL&#xD;
&#xD;
          -  Screening calculated ejection fraction of &gt;= 50% by multiple gated acquisition (MUGA)&#xD;
             scan or echocardiogram; metastatic progression on primary androgen-deprivation therapy&#xD;
             (medical or surgical castration)&#xD;
&#xD;
          -  Progression requiring a change in oncologic therapy defined by any of the following:&#xD;
&#xD;
               -  Radiographic progression: appearance or increase in measurable lesions on&#xD;
                  cross-sectional imaging or appearance of one or more new lesions on bone scan *&#xD;
                  Rising PSA (&gt;= 2 ng/ml) which has risen on two occasions &gt;= 1 week apart&#xD;
&#xD;
               -  Clinical progression evidenced by increased pain or other cancer-related symptoms&#xD;
&#xD;
          -  Patients should have recovered from prior oncologic therapies to a Common Terminology&#xD;
             Criteria (CTC) grade =&lt; 1 except stable neuropathy or alopecia at National Cancer&#xD;
             Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade =&lt; 2; if&#xD;
             rapid clinical progression is documented by imaging, changes in PSA, or symptoms, then&#xD;
             study treatment can begin &gt;= 2 weeks from prior therapy; otherwise, the following time&#xD;
             periods between prior anti-cancer therapies and study treatment day 1 will apply:&#xD;
&#xD;
               -  &gt;= 3 weeks for prior cytotoxic therapies&#xD;
&#xD;
               -  &gt;= 4 weeks for flutamide or nilutamide&#xD;
&#xD;
               -  &gt;= 6 weeks for bicalutamide&#xD;
&#xD;
               -  &gt;= 6 weeks since bone targeted radiopharmaceutical (e.g. samarium-153,&#xD;
                  radium-223)&#xD;
&#xD;
          -  Gonadotropin-releasing hormone (GnRH) agonists (leuprolide acetate, goserelin, etc.)&#xD;
             or antagonists (degarelix, etc.) should be continued in patients without&#xD;
             surgically-induced castrate androgen levels&#xD;
&#xD;
          -  For chemotherapy na√Øve castration-resistant prostate cancer who are moderately&#xD;
             symptomatic or who have hepatic metastasis: subjects must not be a candidate for&#xD;
             docetaxel-based chemotherapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of myocardial infarction, unstable symptomatic ischemic heart disease, ongoing&#xD;
             arrhythmias of grade &gt; 2 (NCI CTCAE, version 4), thromboembolic events (e.g., deep&#xD;
             vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), or any&#xD;
             other cardiac condition (e.g. pericardial effusion, restrictive cardiomyopathy) within&#xD;
             6 months prior to first dose of study drug; chronic stable atrial fibrillation on&#xD;
             stable anticoagulant therapy is allowed&#xD;
&#xD;
          -  New York Heart Association class III or IV heart failure&#xD;
&#xD;
          -  Electrocardiogram (ECG) abnormalities of:&#xD;
&#xD;
               -  Q-wave infarction, unless identified 6 or more months prior to screening&#xD;
&#xD;
               -  Corrected QT (QTc) interval &gt; 460 msec&#xD;
&#xD;
          -  Patient has received other investigational drugs within 28 days before enrollment&#xD;
&#xD;
          -  Diagnosed or treated for another malignancy within 2 years of enrollment, with the&#xD;
             exception of complete resection of basal cell carcinoma or squamous cell carcinoma of&#xD;
             the skin, an in situ malignancy&#xD;
&#xD;
          -  Known hypersensitivity to compounds related to TAK-700 or to TAK-700 excipients&#xD;
&#xD;
          -  Uncontrolled hypertension despite appropriate medical therapy (blood pressure [BP] of&#xD;
             greater than 160 mmHg systolic and 90 mmHg diastolic at 2 separate measurements no&#xD;
             more than 60 minutes apart during the screening visit); Note: patients may be&#xD;
             rescreened after adjustment of antihypertensive medications&#xD;
&#xD;
          -  Known active chronic hepatitis B or C, life-threatening illness unrelated to cancer,&#xD;
             or any serious medical or psychiatric illness that could, in the investigator's&#xD;
             opinion, potentially interfere with participation in this study&#xD;
&#xD;
          -  Likely inability to comply with the protocol or cooperate fully with the investigator&#xD;
             and site personnel&#xD;
&#xD;
          -  Known gastrointestinal (GI) disease or GI procedure that could interfere with the GI&#xD;
             absorption or tolerance of TAK-700, including difficulty swallowing tablets&#xD;
&#xD;
          -  Prior treatment with &gt;= 3 lines of cytotoxic chemotherapy for metastatic prostate&#xD;
             cancer&#xD;
&#xD;
          -  Prior treatment with TAK-700&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell Gross</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>May 28, 2013</study_first_submitted>
  <study_first_submitted_qc>May 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2013</study_first_posted>
  <results_first_submitted>July 3, 2017</results_first_submitted>
  <results_first_submitted_qc>July 31, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 31, 2017</results_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited at the University of Southern California (USC) medical clinics from December 2013 to February 2014. Due to results of two phase III clinical trials in metastatic, castration resistant prostate cancer (mCRPC), the sponsor determined that the drug has not demonstrated a clinical profile sufficient to move forward in mCRPC.</recruitment_details>
      <pre_assignment_details>The trial had no pre-assignment criteria. All subjects were given the same treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Orteronel)</title>
          <description>Patients receive orteronel 300 mg PO BID (twice a day) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
orteronel: Given PO&#xD;
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Orteronel)</title>
          <description>Patients receive orteronel 300 mg PO twice daily (BID) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
orteronel: Given PO&#xD;
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Androgen Receptor (AR) Protein Expression Levels in CTCs</title>
        <description>The two-sample t-test will be used. Once association between AR protein expression levels and response is established, graphical methods such as receiver-operator curves (ROC) or more quantitative methods such as the maximal chi-square method to determine whether there might be a cut-point with either great sensitivity or great specificity (or both) for identifying a cohort with either a high or low likelihood of prostate-specific antigen (PSA) response.</description>
        <time_frame>Up to 4 weeks</time_frame>
        <population>Only 4 patients were accrued to this trial. No data analysis was performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Orteronel)</title>
            <description>Patients receive orteronel 300 mg PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
orteronel: Given PO&#xD;
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Androgen Receptor (AR) Protein Expression Levels in CTCs</title>
          <description>The two-sample t-test will be used. Once association between AR protein expression levels and response is established, graphical methods such as receiver-operator curves (ROC) or more quantitative methods such as the maximal chi-square method to determine whether there might be a cut-point with either great sensitivity or great specificity (or both) for identifying a cohort with either a high or low likelihood of prostate-specific antigen (PSA) response.</description>
          <population>Only 4 patients were accrued to this trial. No data analysis was performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PSA Response, Defined as Occurrence of PSA Decline to Greater Than or Equal to 50% From Baseline</title>
        <description>Standard descriptive methods will be used to summarize PSA. Values will be tabulated as outlined in the Prostate Cancer Working Group 2 (PCWG2) criteria and presented as Kaplan-Meier survival curves, as appropriate.</description>
        <time_frame>At 12 weeks</time_frame>
        <population>Only 4 patients were accrued to this trial. No data analysis was performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Orteronel)</title>
            <description>Patients receive orteronel 300 mg PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
orteronel: Given PO&#xD;
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>PSA Response, Defined as Occurrence of PSA Decline to Greater Than or Equal to 50% From Baseline</title>
          <description>Standard descriptive methods will be used to summarize PSA. Values will be tabulated as outlined in the Prostate Cancer Working Group 2 (PCWG2) criteria and presented as Kaplan-Meier survival curves, as appropriate.</description>
          <population>Only 4 patients were accrued to this trial. No data analysis was performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best PSA Response</title>
        <description>Values will be tabulated as outlined in the PCWG2 criteria and presented as Kaplan-Meier survival curves, as appropriate.</description>
        <time_frame>Up to 24 weeks</time_frame>
        <population>Only 4 patients was accrued to this trial. No data analysis was performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Orteronel)</title>
            <description>Patients receive orteronel 300 mg PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
orteronel: Given PO&#xD;
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Best PSA Response</title>
          <description>Values will be tabulated as outlined in the PCWG2 criteria and presented as Kaplan-Meier survival curves, as appropriate.</description>
          <population>Only 4 patients was accrued to this trial. No data analysis was performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in PSA</title>
        <description>Values will be tabulated as outlined in the PCWG2 criteria and presented as Kaplan-Meier survival curves, as appropriate.</description>
        <time_frame>Baseline to 24 weeks</time_frame>
        <population>Only 4 patients was accrued to this trial. No data analysis was performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Orteronel)</title>
            <description>Patients receive orteronel 300 mg PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
orteronel: Given PO&#xD;
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in PSA</title>
          <description>Values will be tabulated as outlined in the PCWG2 criteria and presented as Kaplan-Meier survival curves, as appropriate.</description>
          <population>Only 4 patients was accrued to this trial. No data analysis was performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 and PCWG2 Criteria</title>
        <description>Response will be tabulated descriptively with 95% confidence intervals (CIs) and Kaplan-Meier survival curves, as appropriate.</description>
        <time_frame>Up to 3 years</time_frame>
        <population>Only 4 patients was accrued to this trial. No data analysis was performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Orteronel)</title>
            <description>Patients receive orteronel 300 mg PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
orteronel: Given PO&#xD;
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 and PCWG2 Criteria</title>
          <description>Response will be tabulated descriptively with 95% confidence intervals (CIs) and Kaplan-Meier survival curves, as appropriate.</description>
          <population>Only 4 patients was accrued to this trial. No data analysis was performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response Using RECIST Version 1.1 and PCWG2 Criteria</title>
        <description>Response will be tabulated descriptively with 95% CIs and Kaplan-Meier survival curves, as appropriate.</description>
        <time_frame>Up to 3 years</time_frame>
        <population>Only 4 patients was accrued to this trial. No data analysis was performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Orteronel)</title>
            <description>Patients receive orteronel 300 mg PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
orteronel: Given PO&#xD;
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response Using RECIST Version 1.1 and PCWG2 Criteria</title>
          <description>Response will be tabulated descriptively with 95% CIs and Kaplan-Meier survival curves, as appropriate.</description>
          <population>Only 4 patients was accrued to this trial. No data analysis was performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Grade 3 or Higher Toxicity</title>
        <description>Summary of grade 3 (per Common Terminology Criteria for Adverse Events (CTCAE v4.0) or higher toxicities which generally is described as a severe reaction or symptom.</description>
        <time_frame>30 days</time_frame>
        <population>Tracked during treatment period until 30 days after last dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Orteronel)</title>
            <description>Patients receive orteronel 300 mg PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
orteronel: Given PO&#xD;
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade 3 or Higher Toxicity</title>
          <description>Summary of grade 3 (per Common Terminology Criteria for Adverse Events (CTCAE v4.0) or higher toxicities which generally is described as a severe reaction or symptom.</description>
          <population>Tracked during treatment period until 30 days after last dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Days 1, 8, 15, 21 of each cycle and treatment end (30 days after last dose or start of new treatment).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Orteronel)</title>
          <description>Patients receive orteronel 300 mg PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
orteronel: Given PO&#xD;
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain - cardiac</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abodminal Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT corrected interval prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial was terminated early due to the discontinuation of the development program for the study drug, TAK-700 (orteronel) for prostate cancer.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Victoria Soto, Project Specialist</name_or_title>
      <organization>USC Norris Comprehensive Cancer Center</organization>
      <phone>323-865-0454</phone>
      <email>Victoria.Soto@med.usc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

